2018-03-14
An update on NextCell Pharma and Nordic Tech House
NextCell Pharma’s (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders’ preferential rights.
NextCell Pharma buys services from Nordic Tech House to increase exposure of NextCell Pharma and Cellaviva, both to inform about its development of stem cell therapies and stem cell saving and to optimize the digital messaging for the next 2 years. For its Nordic Tech House is paid with shares in NextCell Pharma AB through
NextCell Pharma’s (NXTCL) Board decided on 2018-03-13 to utilize its authorization to implement a targeted issue to Nordic Tech House. NextCell Pharma has identified Nordic Tech House as a strategic partner, which justifies deviation from shareholders’ preferential rights.
NextCell Pharma buys se...
Read moreRead more2018-03-14
Nordic Tech House to invest in stem cell company NextCell Pharma
NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva.
The two-year agreement means that Nordic Tech House will be responsible for the total digital presence of NXTCL, with a specific focus on the family stem cell saving service that is offered to expectant parents through the Cellaviva trademark. Isabella Löwengrip, one of the co-owners of Nordic Tech House, will as influencer, mother, entrepreneur and investor increase the
NextCell Pharma (NXTCL), traded at AktieTorget, announces that a collaboration with Nordic Tech House has been agreed upon where Nordic Tech House will invest in NXTCL and develop the digital presence of NXTCL and Cellaviva.
The two-year agreement means that Nordic Tech House will be responsible ...
Read moreRead more2018-03-06
NextCell CEO invited speaker at the Swedish National ATMP Conference
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th.
The topic of the lecture will be ‘Mesenchymal Stem Cells in Clinical Trials for Treatment of Autoimmune Diseases’. More specifically it describes, how NXTCL leads the way with the development of its drug candidate, ProTrans, using pooled mesenchymal stem cells form the umbilical cord.
NXTCL is currently conducting a phase I/II trial using its drug candidate ProTrans for the treatment of adult
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th.
The topic of the lecture will be ‘Mesenchymal Stem Cells in Clinical Trials for Treatment of Autoi...
Read moreRead more2018-02-22
Three patients now treated with NextCells ProTrans stem cells
NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated with
ProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have now
undergone treatment.
The trial performed with NXCTCL's patent-pending ProTrans, is divided into two parts, the first part being a doseescalation
phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now
that all patients in the low-dose-cohort have been treated and after the 1-month follow-up is completed we can
start inclusion of patients in the
NextCell Pharma AB ("NXTCL") announces that three type 1 diabetes patients have been treated with
ProTrans in the ongoing clinical phase I/II trial. Thus, all patients in the low-dose-cohort have now
undergone treatment.
The trial performed with NXCTCL's patent-pending ProTrans, is divided into t...
Read moreRead more2018-02-16
NextCell Pharma files patent application
NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans.
The selection algorithm is based on multiple functional assays used to identify and select cells and donors with
specified desired characteristics. ProTrans is a pooled allogeneic stem cell product, consisting of cells from multiple
donors. The pooling process supports the production of large batches. The combination
NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company’s proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans.
The selection algorith...
Read moreRead more2018-01-31
NextCell Pharma changes ticker to NXTCL
NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL.
Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has
decided to change the ticker to NXTCL. The new abbreviation might also be used in general market communications
and company branding.
The new ticker will become effective as per 2018-02-07, the company name and ISIN-code (SE0009723125) will
remain the same.
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse
Regulation.
NextCell Pharma AB ("NextCell") announces that it will change its ticker on Aktietorget to NXTCL.
Since its listing on Aktietorget (2017-07-13), NextCell has been traded using the ticker NEXTCL. Management has
decided to change the ticker to NXTCL. The new abbreviation might also be used in gener...
Read moreRead more2018-01-24
First diabetes patient treated with ProTrans stem cells
NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a maximum of two years.
The clinical trial started on November 28th, 2017 and after clinical assessment and baseline data collection, the first patient has now been treated (first-in-human) with ProTrans stem cells.
The first part of the study is a three-step dose escalation with three patients in each
NextCell Pharma AB ("NextCell") announces that the first patient with type 1 diabetes has now been treated with the company's drug candidate ProTrans. The clinical trial evaluates the safety and efficacy of ProTrans after treatment of patients 18-40 years old and who had type 1 diabetes for a max...
Read moreRead more2017-11-29
NextCell Pharma initiates stem cell trial for type 1-diabetes with ProTrans
NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving ProTrans stem cell treatment. Patients with type 1-diabetes being 18-40 years who received their diagnosis no later than 2 years ago and still have some insulin production are candidates for participation in the trial.
NextCell Pharma has reached a new level as a company. I would like to thank all the
NextCell Pharma AB ("NextCell") announces that the initiation meeting for the clinical trial in which drug candidate ProTrans will be evaluated, was held on November 28th, 2017. The trial will investigate safety as well as evaluate the patient’s own insulin production 12 months after receiving Pr...
Read moreRead more